CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
REVENUES:
Net product sales	$ 19,322,302	$ 13,680,107	$ 21,886,688
License and royalty revenue	741,534	449,685	52,753
R&D, milestone and grant revenue	3,951,591	3,739,049	2,316,044
TOTAL REVENUES	24,015,427	17,868,841	24,255,485
COSTS AND EXPENSES:
Cost of product sales	12,921,157	9,417,505	13,768,658
Research and development expenses	8,555,381	8,427,554	6,377,839
Selling, general and administrative expenses	9,021,439	7,595,559	7,663,035
TOTAL OPERATING EXPENSES	30,497,977	25,440,618	27,809,532
LOSS FROM OPERATIONS	(6,482,550)	(7,571,777)	(3,554,047)
OTHER INCOME (EXPENSE):
Other expense	0	0	(4,814)
Interest income	25,430	25,548	2,412
Interest expense	(2,945)	0	(836)
TOTAL OTHER INCOME	22,485	25,548	(3,238)
LOSS BEFORE INCOME TAXES (BENEFIT)	(6,460,065)	(7,546,229)	(3,557,285)
Income tax provision (benefit)	(88,305)	5,800,818	(1,160,243)
NET LOSS	$ (6,371,760)	$ (13,347,047)	$ (2,397,042)
Basic loss per share (in dollars per share)	$ (0.52)	$ (1.26)	$ (0.25)
Diluted loss per share (in dollars per share)	$ (0.52)	$ (1.26)	$ (0.25)
Weighted average number of shares outstanding, basic (in shares)	12,300,031	10,622,331	9,626,028
Weighted average number of shares outstanding, diluted (in shares)	12,300,031	10,622,331	9,626,028